Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTX NASDAQ:BMRA NASDAQ:IMNN NASDAQ:KZIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.03-5.5%$1.34$1.02▼$21,400.00$2.31M1.5857,112 shs217,306 shsBMRABiomerica$3.15-2.8%$3.30$1.93▼$10.16$8.25M0.2670,894 shs18,448 shsIMNNImunon$8.50+2.5%$15.34$5.55▼$47.40$11.78M1.93424,492 shs106,176 shsKZIANovogen$8.18-2.4%$7.63$2.86▼$39.05$8.44M2.64640,999 shs935,663 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-5.50%-13.45%-17.60%-53.81%-99.99%BMRABiomerica-2.78%-19.44%-2.48%-12.74%+18.99%IMNNImunon+2.53%+21.43%-29.17%-32.31%-58.02%KZIANovogen-2.39%-16.70%+24.32%+114.14%-56.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxtN/AN/AN/AN/AN/AN/AN/AN/ABMRABiomerica0.2054 of 5 stars0.03.00.00.00.60.80.0IMNNImunon2.4583 of 5 stars3.45.00.00.01.60.00.6KZIANovogen3.0795 of 5 stars3.83.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/ABMRABiomerica 0.00N/AN/AN/AIMNNImunon 2.75Moderate Buy$232.502,635.29% UpsideKZIANovogen 3.50Strong Buy$14.0071.15% UpsideCurrent Analyst Ratings BreakdownLatest ADTX, BMRA, IMNN, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025KZIANovogenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$13.006/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/19/2025IMNNImunonD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/13/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$435.00 ➝ $255.005/7/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$435.00 ➝ $435.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$130K16.80N/AN/A($1.52) per share-0.68BMRABiomerica$5.41M1.48N/AN/A$3.13 per share1.01IMNNImunonN/AN/AN/AN/A$4.39 per shareN/AKZIANovogen$1.51M5.47N/AN/A($9.87) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$34.45MN/A0.00∞N/A-46,082.47%-389.10%-84.71%8/18/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/27/2025 (Estimated)IMNNImunon-$18.62M-$20.39N/AN/AN/AN/A-427.98%-175.03%8/5/2025 (Estimated)KZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/ALatest ADTX, BMRA, IMNN, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025IMNNImunon-$0.24N/AN/AN/AN/AN/A5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/12/2025Q1 2025IMNNImunon-$5.25-$4.20+$1.05-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ALatest ADTX, BMRA, IMNN, and KZIA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/28/2025IMNNImunonquarterly$0.158.57%8/7/20258/7/20258/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.080.08BMRABiomericaN/A3.762.76IMNNImunonN/A0.880.88KZIANovogenN/A0.21N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%BMRABiomerica22.28%IMNNImunon4.47%KZIANovogen30.89%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%BMRABiomerica15.00%IMNNImunon5.96%KZIANovogen1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million2.12 millionNo DataBMRABiomerica602.55 million2.16 millionOptionableIMNNImunon301.42 million1.34 millionNot OptionableKZIANovogen121.01 million997,000OptionableADTX, BMRA, IMNN, and KZIA HeadlinesRecent News About These CompaniesKazia Therapeutics Announces $2 Million Private Placement at Premium to MarketAugust 1 at 8:00 AM | prnewswire.comNovogen (NASDAQ:KZIA) Rating Increased to Hold at Wall Street ZenJuly 26, 2025 | americanbankingnews.comKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 9, 2025 | prnewswire.comKazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast CancerJune 11, 2025 | marketwatch.comKazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)June 11, 2025 | prnewswire.comKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast CancerJune 5, 2025 | prnewswire.comKazia Therapeutics Highlights Recent Progress and Provides Business UpdateMay 15, 2025 | prnewswire.comVivesto AB: Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rightsMarch 31, 2025 | finanznachrichten.deKazia Therapeutics sells IP, trademarks rights to Cantrixil for $1MMarch 31, 2025 | markets.businessinsider.comKazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for CantrixilMarch 31, 2025 | prnewswire.comKazia Therapeutics announces research grant awarded from MJFFFebruary 20, 2025 | markets.businessinsider.comMaxim Group Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt () (KZIA) with Buy RecommendationFebruary 8, 2025 | msn.comMaxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study dataFebruary 6, 2025 | markets.businessinsider.comKazia Therapeutics initiated with a Buy at MaximFebruary 6, 2025 | markets.businessinsider.comKazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast CancerJanuary 31, 2025 | appliedclinicaltrialsonline.comAIs Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?January 31, 2025 | msn.comKazia Therapeutics launches trial of paxalisib/immunotherapy combinationJanuary 30, 2025 | markets.businessinsider.comWhy Kazia Therapeutics (KZIA) Is Surging: A Big Bet on Breast Cancer BreakthroughsJanuary 30, 2025 | bovnews.comBKazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerJanuary 30, 2025 | prnewswire.comWhy Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?January 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADTX, BMRA, IMNN, and KZIA Company DescriptionsAditxt NASDAQ:ADTX$1.03 -0.06 (-5.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Biomerica NASDAQ:BMRA$3.15 -0.09 (-2.78%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.32 +0.18 (+5.56%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Imunon NASDAQ:IMNN$8.50 +0.21 (+2.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.39 -0.11 (-1.29%) As of 08/1/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Novogen NASDAQ:KZIA$8.18 -0.20 (-2.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.96 -0.23 (-2.75%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
